Neeraj Agarwal

Neeraj Agarwal leads the GU oncology program at Huntsman Cancer Institute and has been an active contributor to nmCRPC clinical trials including the SPARTAN study. His research focuses on the safety and tolerability of AR pathway inhibitors in real-world prostate cancer populations, cardiovascular risks, and quality of life considerations. He has published extensively on treatment selection frameworks for patients with non-metastatic CRPC based on PSA kinetics and comorbidities. Agarwal mentors the next generation of GU oncologists and leads investigator-initiated trials.